PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19100788-11	2009	DFX reduces free iron levels and attenuates activation of JNK suggesting iron chelation may be useful therapy for ICH patients.	Deferoxamine	0-3	mitogen-activated protein kinase 8	Homo sapiens	58-61	
21378396-5	2011	Examination of the phosphorylation of major MAPKs revealed that DFO and Dp44mT markedly increased phosphorylation of stress-activated protein kinases, JNK and p38, without significantly affecting the extracellular signal-regulated kinase (ERK).	Deferoxamine	64-67	mitogen-activated protein kinase 8	Homo sapiens	151-154	
21378396-7	2011	Iron or N-acetylcysteine supplementation reversed Dp44mT-induced up-regulation of phospho-JNK, but only iron was able to reverse the effect of DFO on JNK.	Deferoxamine	143-146	mitogen-activated protein kinase 8	Homo sapiens	150-153	
20206247-6	2010	Pretreatment with antioxidants and an iron chelator, deferoxamine suppressed ROS production, ASK1, JNK1/2 and p38 MAPK activation, and reduced cell death after STE exposure.	Deferoxamine	53-65	mitogen-activated protein kinase 8	Homo sapiens	99-105	
18187175-6	2008	DFX treatment activated two MAPKs, p38 and JNK, and induced the phosphorylation of two proteins in the p38 pathway, MKK3 and MKK6.	Deferoxamine	0-3	mitogen-activated protein kinase 8	Homo sapiens	43-46	
15913932-4	2005	DFX also induced the activation of mitogen-activated protein kinase (MAPK) including p38, ERK, and JNK on HEI-OC1.	Deferoxamine	0-3	mitogen-activated protein kinase 8	Homo sapiens	99-102	
12657244-3	2002	We report that the chelator deferoxamine (DFO) strongly activates both p38 MAP kinase and extracellular signal-regulated kinase (ERK) at an early stage of incubation, but slightly activates c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) at a late stage of incubation.	Deferoxamine	28-40	mitogen-activated protein kinase 8	Homo sapiens	247-255	
12657244-3	2002	We report that the chelator deferoxamine (DFO) strongly activates both p38 MAP kinase and extracellular signal-regulated kinase (ERK) at an early stage of incubation, but slightly activates c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) at a late stage of incubation.	Deferoxamine	42-45	mitogen-activated protein kinase 8	Homo sapiens	247-255	
35127502-8	2021	This reprogramming might be responsible for mitochondrial iron-sulfur (Fe-S) cluster biogenesis, which has become an "Achilles" heel," rendering cancer cells vulnerable to DFO-induced autophagic cell death and apoptosis through c-Jun N-terminal kinase (JNK) signaling.	Deferoxamine	172-175	mitogen-activated protein kinase 8	Homo sapiens	228-251	
35127502-8	2021	This reprogramming might be responsible for mitochondrial iron-sulfur (Fe-S) cluster biogenesis, which has become an "Achilles" heel," rendering cancer cells vulnerable to DFO-induced autophagic cell death and apoptosis through c-Jun N-terminal kinase (JNK) signaling.	Deferoxamine	172-175	mitogen-activated protein kinase 8	Homo sapiens	253-256	
31238089-13	2019	DFO augmented production of mitochondrial ROS, but inhibited the phosphorylation of ERK1/2, JNK, and p38, even in the presence of hydrogen peroxide.	Deferoxamine	0-3	mitogen-activated protein kinase 8	Homo sapiens	92-95